Tethis, MACS, and Everex Forge Robust Alliance for See.d® Business Unit Transfer and Future Collaboration

Tethis, MACS, and Everex Forge Robust Alliance for See.d® Business Unit Transfer

In a significant move for the biotechnology field, Tethis S.p.A., MACS S.r.l., and Everex S.r.l. have completed the transfer of the See.d® business unit from MACS to Tethis on September 21, 2026. This collaboration, which includes a long-term manufacturing partnership with Everex, emphasizes the companies' shared commitment to advancing liquid biopsy technology and improving diagnostic procedures.

The innovative See.d platform is designed to standardize the preparation of blood-derived cellular samples, which is essential for reproducible liquid biopsy applications, digital cytology, and AI-assisted analysis. By enabling the extraction of both plasma for cfDNA analysis and preserved nucleated cells from a single blood sample, the See.d technology optimizes workflows and addresses the growing demand for efficiency and quality in medical diagnostics.

This strategic transfer grants Tethis full control over the development and commercialization of the See.d platform, along with its associated intellectual property and engineering expertise previously held by MACS. Everex, renowned for its capabilities in manufacturing in-vitro diagnostic instruments, will play a crucial role in supporting the production and future scale-up of this vital technology. Their involvement promises not only reliability in manufacturing but also the capacity for rapid improvements and adaptations as the technology gains wider acceptance in the medical community.

Holger Neecke, CEO of Tethis, views this acquisition as a pivotal strategic step. He emphasizes that having the See.d technology and engineering expertise entirely in-house empowers Tethis to refine a key component of their liquid biopsy workflow. He expresses optimism about building on the strong foundations laid alongside MACS and Everex, setting the stage for future developments and expansions of the platform.

Andrea Eugeni, CEO of MACS, expressed satisfaction with the transition, noting that the See.d business unit's journey continues within the organization that has nurtured its scientific application over the years. He underlines the successful collaboration that has led to significant achievements, and he believes that Tethis is the ideal environment for the technology's ongoing growth and development.

Lorenzo Balli, CEO of Everex, shares the enthusiasm for the expanded collaboration with Tethis. He points out that Everex's expertise in developing and manufacturing intelligent diagnostic instruments places the company in an excellent position to contribute to the ongoing success of See.d. This proactive approach to industrialization and regulated production aligns with their commitment to supporting technological advancements in the in-vitro diagnostics sphere.

The performance of the See.d technology has been rigorously validated through extensive technical and clinical evaluations. It has already made a mark in clinical studies, including a noteworthy feasibility study at the European Institute of Oncology (IEO) in Milan. The platform is also currently utilized in research initiatives at prestigious institutions such as Sheba Medical Center, Weill Cornell Medicine, and ETH Zurich. These collaborations highlight the platform’s contributions to advancing workflows focused on the characterization of circulating tumor cells.

Overview of See.d® Technology

The See.d platform serves as an automated pre-analytical blood processing system. It is designed to produce standardized liquid biopsy workflows, generating both plasma and cellular preparations from a single blood sample. The system streamlines various processes—including plasma separation, red blood cell lysis, and the deposition of nucleated cells onto Tethis' patented SmartBioSurface® slides—facilitating comprehensive analysis of circulating tumor cells, immune cells, cell-free DNA, and other blood-derived biomarkers.

Tethis S.p.A. has established itself as a key player in the life sciences and diagnostics sectors, focusing on innovative workflows for high-quality sample preparation and cellular analysis. The company's SmartBioSurface® technology, characterized by a proprietary nanostructured titanium coating, enhances the efficiency of cell adhesion, paving the way for diverse applications such as imaging and multiplex assays. This synergetic technology, when paired with the See.d instrument, allows for meticulous preparation of blood samples while maintaining specimen integrity and enabling advanced AI-driven analysis.

Headquartered in Milan, Italy, Tethis continues to push the boundaries of what is possible in liquid biopsy, fostering collaborations that will drive future innovations and ultimately improve patient outcomes in clinical settings. The successful integration of the See.d business unit exemplifies the company’s ambitious vision and commitment to advancing diagnostic science.